Inside Downey 2011: The Study Behind "Smart Delivery"
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
If you have read anything PureLift LAB has published in the last six months about EMS technology, you have almost certainly seen one citation appear over and over: Downey et al., 2011. We reference this paper because the research it documents is the empirical backbone for what we mean when we say "smart delivery." This article unpacks what that study actually tested, what it found, and why one specific finding — that varied-frequency stimulation outperformed constant-frequency stimulation in maintaining muscle performance over repeated contractions — is the engineering principle that defines a category of device.
The paper, in brief
The full citation: Downey RJ, Bellman M, Sharma N, Wang Q, Gregory CM, Dixon WE. (2011). A novel modulation strategy to increase stimulation duration in neuromuscular electrical stimulation. Muscle & Nerve 44(3):382–387. The work was carried out at the University of Florida — the Department of Mechanical and Aerospace Engineering and the Brain Rehabilitation Research Center — and published in Muscle & Nerve, one of the standard peer-reviewed journals for clinical neuromuscular research.
What the study set out to investigate
Downey and colleagues examined a problem that had been quietly limiting electrical-stimulation therapy for decades: the rapid onset of muscle fatigue during repeated NMES contractions. The opening framing of their paper, in their words: "A fundamental barrier to NMES treatments is the rapid onset of muscle fatigue. The onset of muscle fatigue during electrical stimulation is strongly correlated with stimulation parameters such as intensity, frequency, and pattern of stimulation."
The clinical observation behind the work is well-established. When a muscle is repeatedly contracted in response to a fixed electrical stimulation pattern, the response progressively weakens. Each contraction produces less force than the last. The decline is not a perception issue; it is a measurable consequence of how the stimulation interacts with the muscle's metabolic and neuromuscular machinery.
What they measured
The research team compared four stimulation protocols on the quadriceps femoris muscle group of healthy adult participants, with leg motion controlled to follow a defined sinusoidal trajectory:
- Protocol 1: Constant 20 Hz stimulation
- Protocol 2: Constant 40 Hz stimulation
- Protocol 3: Decreasing frequency, 40 Hz down to 20 Hz
- Protocol 4: Increasing frequency, 20 Hz up to 40 Hz
The metric was Successful Run Time (SRT) — how long the muscle could continue producing target contractions before failing to track the desired trajectory. Across 12 healthy legs, the mean SRTs in seconds:
- Constant 20 Hz: 103.3 seconds
- Constant 40 Hz: 59.4 seconds
- Decreasing 40→20 Hz: 187.8 seconds
- Increasing 20→40 Hz: 166.4 seconds
Both varied-frequency protocols produced statistically significantly longer SRTs than both constant-frequency protocols. The same closed-loop force-control approach was used across all four protocols, so the between-protocol comparison supports the incremental value of changing frequency.
The conclusion the authors drew
The authors concluded that varied-frequency protocols performed better than constant-frequency protocols under their closed-loop quadriceps conditions. Because force control was common to all protocols, the between-protocol comparison supports varied frequency. Frequency is the verified continuously varied PureLift parameter.
The Downey study supports a within-protocol conclusion: in the tested quadriceps model, varied-frequency protocols sustained target contractions longer than constant-frequency protocols. It did not test PureLift, facial muscles, or effectiveness across weeks or months, so it should not be used to claim that a fixed-frequency facial device inevitably declines from one session to the next.
The transferable principle is narrower. Changing frequency can alter fatigue and sustained-force performance relative to holding frequency constant. PureLift applies that principle through Dynamic Modulation™, which cycles through 361 frequencies from 1,370 to 1,730 Hz. This is an engineering rationale, not proof that fatigue or accommodation is eliminated.
The metabolic mechanism
The paper offers a specific physiological explanation worth understanding. From the discussion: "During repeated contractions, a significant amount of energy is utilized for Ca++ release/reuptake, and the combination of slowing of temporal characteristics with a lower activation frequency could result in a net benefit during this stage of the protocols."
In plain terms: every muscle contraction requires the cell to release calcium to trigger the contractile apparatus, then pump that calcium back across membranes to allow relaxation. This calcium cycling is metabolically expensive. When the stimulation pattern is fixed, the same calcium-cycling load lands on the same fiber populations repeatedly, and the energy budget for that cycling depletes faster than when the pattern varies.
Real Power. Smart Delivery.
This is the principle behind the phrase. Real power means usable amplitude sufficient for motor-level activation. Smart delivery means deliberate frequency modulation. In PDM™, Dynamic Modulation™ cycles through 361 frequencies from 1,370 to 1,730 Hz, while Triple-Wave™ layers three simultaneous depth-oriented components. Downey supports the frequency-delivery principle; it does not establish distribution across particular fiber populations. Frequency is the verified continuously varied PureLift parameter.
What the study did not claim
For accuracy and intellectual honesty, two important caveats:
First, the study was conducted on quadriceps tissue, not facial musculature. Facial muscles are smaller, more superficial, and innervated differently than skeletal muscle in the legs. The general principle of fatigue-rate dependence on stimulation pattern transfers — neuromuscular biology shares core mechanisms across muscle groups — but the specific SRT numbers from this study are not a direct prediction of facial EMS session behavior.
Second, the frequencies tested were 20–40 Hz, the conventional range for clinical NMES. PureLift devices operate in the 1.37–1.73 kHz operating band, which uses a different waveform architecture (alternating current burst frequency rather than direct pulse rate). The principle that varied frequency outperforms constant frequency for sustained performance applies across both contexts in principle, but the kHz operating range was not directly tested in this study.
We cite the Downey et al. paper for the architectural principle — modulation produces sustained performance, fixed frequency does not — not as a clinical endorsement of any specific device.
How this maps to PureLift's engineering
PureLift devices are engineered around three principles that are consistent with the Downey et al. findings:
- Operating frequency band: 1.37–1.73 kHz, a band associated with deep muscle engagement rather than surface skin stimulation.
- Dynamic Modulation™: the frequency cycles through 361 points from 1,370 to 1,730 Hz and is engineered to reduce accommodation relative to fixed-frequency delivery. The cited evidence supports varied frequency in general, not guaranteed elimination of accommodation.
- Diamond-faceted probe geometry on Pro Plus and Glow: the patented design supports steadier skin contact and controlled glide across facial contours. The supplied evidence does not establish uniform current distribution or fiber engagement from probe shape.
Each principle is engineering, not marketing. The Downey et al. paper gives us empirical confidence in the second one. For the others, we lean on conductivity research, contact-area physics, and the published literature on muscle-fiber recruitment thresholds. We discuss those separately in our Smarter Power piece.
The takeaway
If you remember one point from this paper, it should be that varied-frequency protocols sustained target contractions longer than constant-frequency protocols under the tested conditions. Smart delivery in PDM™ refers to frequency modulation, while real power refers to usable amplitude sufficient for motor-level activation. The evidence supports those as separate engineering dimensions; it does not guarantee session-after-session outcomes or the absence of a plateau.
For the deeper mechanism walk-through, see Modulated vs. Fixed Frequency EMS. For the practical question of what session cadence makes sense given how the body adapts, our Future of Facial EMS article walks through the dose curve.
The PureLift Pro Plus with Activator Serum combines up to 9 mA output with PDM™. Dynamic Modulation™ cycles through 361 frequencies from 1,370 to 1,730 Hz, Triple-Wave™ layers three simultaneous depth-oriented components, and the conductive medium supports consistent contact.
Reference: Downey RJ, Bellman M, Sharma N, Wang Q, Gregory CM, Dixon WE. (2011). A novel modulation strategy to increase stimulation duration in neuromuscular electrical stimulation. Muscle & Nerve 44(3):382–387. DOI: 10.1002/mus.22058.